Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
JP Morgan analyst Jessica Fye raised her price target on MRNA to $77 from $40 — a 93% jump. The stock stays rated Sell. That gap between a rising target and a bearish rating is unusual. Short interest sits at 13.3% of free float, signaling skepticism remains widespread.
At a $53 billion market cap, Moderna continues to divide Wall Street. The raised target likely reflects pipeline optionality rather than a change in fundamental view.
Ross Stores Gets a Lift
JP Morgan's Matthew Boss upgraded ROST to Buy and lifted his target to $272 from $262. The off-price retailer carries just 3% SI % FF — short sellers are not crowding this name. With consumer spending holding up, Boss sees value in the discount retail trade.
Deere Draws Multiple Upgrades
DE received two separate target price increases today. JP Morgan's Tami Zakaria lifted to $585 from $570. The consensus average moved up to $659. At a $168 billion market cap, sentiment on the farm equipment giant is turning more constructive.
Utilities Face Pressure
Morgan Stanley's David Arcaro cut targets on both EXC and FE. Exelon was trimmed to $53, FirstEnergy to $52. Both remain rate-sensitive names in a tricky macro environment.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
